Merck & Company, Inc. · NYSE:MRK

Merck & — Shareholder Meeting (May 2023)

36 slides from Merck &'s shareholder meeting presentation, May 23, 2023

  1. Slide 1: Annual Meeting of Shareholders

    Annual Meeting of Shareholders May 23, 2023

  2. Slide 2: Forward-looking statement

    Confidential Forward-looking statement This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the cu

  3. Slide 3: Annual Meeting of Shareholders – Robert M. Davis

    Annual Meeting of Shareholders Robert M. Davis Chairman and Chief Executive Officer

  4. Slide 4: Nominees for Director

    Confidential Nominees for Director Robert M. Davis Douglas M. Baker, Jr. Mary Ellen Coe Pamela J. Craig Thomas H. Glocer Risa J. Lavizzo- Mourey, M.D. Stephen L. Mayo, Paul B. Rothman, Patricia F. Russo Christine E. Inge G. Thulin Kathy J. Warden Peter C. Wendell Ph.D. M.D. Seidman, M.D. 4

  5. Slide 5: Leadership transition

    Leadership transition Kenneth C. Frazier Kenneth C. Frazier

  6. Slide 6: Executive team

    Confidential Executive team Robert M. Davis Sanat Chattopadhyay Richard R. DeLuca, Jr. Cristal N. Downing Chirfi Guindo Michael A. Klobuchar Dean Y. Li, M.D., Ph.D. Caroline Litchfield Steven C. Mizell Jannie Oosthuizen Joseph Romanelli Dave Williams Jennifer Zachary 6

  7. Slide 7: €> MERCK

    €> MERCK

  8. Slide 8: Merck's Purpose

    Merck’s Purpose For more than 130 years, Merck has been guided by one clear and compelling purpose: putting patients first and using the power of leading-edge science to save and improve lives. 8

  9. Slide 9: Full-year 2022 highlights

    Confidential Full-year 2022 highlights Financial Highlights (Non-GAAP)* Full Year Human Health Sales vs. Prior 2022 $52.0B Sales $59.3 +22% +22% +28% ex-FX Strong growth in KEYTRUDA, PGM % 74.4% -1.7 ppts GARDASIL/GARDASIL 9 and LAGEVRIO; launch of VAXNEUVANCE Operating Expense $21.6 +3% SG&A Expens

  10. Slide 10: Strong progress in pipeline

    Confidential Strong progress in pipeline Cardiovascular Oncology Vaccines Animal Health 10

  11. Slide 11: Business development to strengthen innovative pipeline

    Confidential Business development to strengthen innovative pipeline 4 programs in oncology sourced through business development will have Phase III trial starts in 2023, with the opportunity to contribute sustainable growth during the latter half of this decade and into the next. Recently, we announ

  12. Slide 12: Sustainability is fundamental to Merck's long-term success

    Confidential Sustainability is fundamental to Merck’s long-term success Environmental Access to Health Employees Ethics & Values Sustainability

  13. Slide 13: €9 MERCK

    €9 MERCK

  14. Slide 14: Annual Meeting of Shareholders – Dean Y. Li

    Annual Meeting of Shareholders Dean Y. Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories

  15. Slide 15: Making tangible advancements in our cardiovascular pipeline: Sotatercept

    Confidential Making tangible advancements in our cardiovascular pipeline Sotatercept • Presented Phase 3 results from the STELLAR trial1 • Substantial improvement of 40.8 meters in 6MWD at Week 24 • Met 8 out of 9 secondary endpoints including: • 84% reduction in risk of death or clinical worsening

  16. Slide 16: Making tangible advancements in our cardiovascular pipeline: MK-0616

    Confidential Making tangible advancements in our cardiovascular pipeline MK-0616 • Presented Phase 2b results • Reduction of LDL-cholesterol levels from 41.2 up to 60.9% vs placebo, across 4 doses in study • 80% to 90% of patients receiving MK-0616 were able to reach their LDL-C goals • Defined path

  17. Slide 17: Leveraging our expertise towards immunology

    Confidential Leveraging our expertise towards immunology 17

  18. Slide 18: Proposed acquisition of Prometheus Biosciences

    Confidential Continuing to advance science-led strategy through proposed acquisition of Prometheus Biosciences Potentially transformational, first-in-class, late-stage candidate, in a disease area with significant unmet medical need Opportunity to potentially transform standard of care for certain p

  19. Slide 19: €> MERCK

    €> MERCK

  20. Slide 20: Nominees for Director

    Confidential Nominees for Director Robert M. Davis Douglas M. Baker, Jr. Mary Ellen Coe Pamela J. Craig Thomas H. Glocer Risa J. Lavizzo- Mourey, M.D. Stephen L. Mayo, Paul B. Rothman, Patricia F. Russo Christine E. Inge G. Thulin Kathy J. Warden Peter C. Wendell Ph.D. M.D. Seidman, M.D. 20

  21. Slide 21: €> MERCK

    €> MERCK

  22. Slide 22: Proposal 5 – Shareholder Proposal

    Proposal 5 – Shareholder Proposal

  23. Slide 23: €> MERCK

    €> MERCK

  24. Slide 24: Proposal 6 – Shareholder Proposal

    Proposal 6 – Shareholder Proposal

  25. Slide 25: €> MERCK

    €> MERCK

  26. Slide 26: Proposal 7 – Shareholder Proposal

    Proposal 7 – Shareholder Proposal

  27. Slide 27: €> MERCK

    €> MERCK

  28. Slide 28: Proposal 8 – Shareholder Proposal

    Proposal 8 – Shareholder Proposal

  29. Slide 29: €> MERCK

    €> MERCK

  30. Slide 30: Proposal 9 – Shareholder Proposal

    Proposal 9 – Shareholder Proposal

  31. Slide 31: €> MERCK

    €> MERCK

  32. Slide 32: Proposal 10 – Shareholder Proposal

    Proposal 10 – Shareholder Proposal

  33. Slide 33: €> MERCK

    €> MERCK

  34. Slide 34: Question & Answer

    € MERCK Question & Answer

  35. Slide 35: €> MERCK

    €> MERCK

  36. Slide 36: Thank you

    Thank you Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. 36

Merck & — Shareholder Meeting (May 2023) on 6ix